Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **blood-labyrinth barrier** (BLB) is not a molecule or receptor, but rather a unique anatomical and physiological barrier system located in the inner ear, specifically in the **stria vascularis** and other cochlear regions[1][3][7]. The BLB is formed by **endothelial cells** joined by tight junctions, **pericytes**, a **basement membrane**, and **perivascular-resident macrophage-like melanocytes**. Its core function is to **limit and regulate the exchange of solutes, metabolites, and toxins between the bloodstream and the inner ear fluids (endolymph, perilymph)**[5][6][7]. It is equivalent in concept to the blood-brain barrier, but specifically maintains the composition and homeostasis of cochlear fluids necessary for hearing[1][3]. The barrier helps protect the ear from systemic toxins and supports essential functions like nutrient supply, ion absorption, and waste excretion[6][7]. BLB dysfunction is a pathological feature in conditions such as Meniere’s disease, sensorineural hearing loss, noise- and drug-induced hearing loss, and autoimmune diseases affecting the ear[2][3][7]. There is **no single molecular target, receptor, or gene designated as "BLB"**. The BLB is considered an *anatomical barrier* and *physiological entity*, not a druggable target like an enzyme or receptor[1][2][5][7]. Recent therapeutic research aims to exploit or traverse the BLB for targeted drug delivery, for example, nanoparticle-based therapies or agents capable of modulating BLB permeability[1][6][7]. However, there are **no drugs that interact directly with "the BLB" as a target**, and it is **not classified under molecular families like receptors, enzymes, or transporters**. **Note:** - This entry is **incorrect if used as a therapeutic molecular target** or if assigned as a classic receptor, enzyme, or transporter. - If you are seeking *molecular targets* within the BLB (like tight junction proteins, transporters, or signaling molecules), further specificity is required.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Blood-labyrinth barrier (BLB).